Bioretec Secures Transitional Pass-Through Payment Status
Bioretec Ltd, a leading innovator in absorbable orthopedic implants, recently achieved significant recognition from the U.S. Centers for Medicare & Medicaid Services (CMS) for its RemeOs™ Trauma Screw. This accolade is the Transitional Pass-Through Payment (TPT) status which began on October 1, 2025. This status acknowledges the innovative nature of Bioretec's technology and supports improved patient outcomes.
Details of the HCPCS Code Update
On January 1, 2026, CMS introduced an important revision to the Healthcare Common Procedure Coding System (HCPCS) Level II codes, which included the code C1741 linked to Bioretec’s RemeOs™ Trauma Screw. The updated descriptor explicitly states: “Anchor/screw bone fixation, absorbable, metallic (implantable).” This change emphasizes the focus on absorbable metallic implants, a sector in which Bioretec is leading the charge.
Regulatory Alignment and Innovation
By revising the descriptor associated with HCPCS code C1741, CMS aligns its definition with existing FDA classifications for absorbable metallic bone fixation devices. This alignment supports the regulatory standards under which the RemeOs™ Trauma Screw obtained both Breakthrough Device Designation and De Novo market authorization, ensuring comprehensive recognition of its innovative nature.
Impact of TPT Payment on Healthcare Providers
The TPT payment system, identified by HCPCS billing code C1741, offers additional reimbursement for hospitals and ambulatory surgical centers investing in new technologies like the RemeOs™ Trauma Screw. This mechanism reduces the financial burden associated with the adoption of these groundbreaking devices, supporting wider access for patients in need of advanced orthopedic treatments.
Groundbreaking Developments with RemeOs™
The RemeOs™ Trauma Screw stands out as the first osteopromotive absorbable metal implant available in the United States. Designed to aid bone healing, this innovative implant gradually degrades and is replaced by the body’s natural bone, thus circumventing the potential complications tied to traditional permanent metallic implants.
Bioretec's Commitment to Orthopedic Innovation
This update in HCPCS code is a reflection of Bioretec’s dedication to shaping the orthopedic field through sustainable solutions. Following the FDA De Novo authorization received in March 2023, this revision bolsters Bioretec’s status as a key player among companies recognized by both healthcare regulators and payors for their clinical and economic contributions.
Focus on Biodegradable Technologies
Bioretec is internationally recognized for its pioneering biodegradable implant technologies. Their latest innovations, particularly the RemeOs™ product line, showcase advancements in high-performance magnesium alloys and hybrid composites. These materials not only promote effective healing but also minimize the need for follow-up surgeries related to implant removal, showcasing a critical shift in orthopedic care.
Activa Product Line for Multiple Indications
In addition to RemeOs™, Bioretec’s Activa product line features a range of bioabsorbable orthopedic implants designed for various applications in both adult and pediatric patient populations. Made from a proprietary, self-reinforced PLGA, these implants are both CE marked and FDA cleared, highlighting Bioretec’s focus on versatile, safe, and innovative solutions for complex orthopedic conditions.
About Bioretec and Future Aspirations
As a Finnish medical device pioneer, Bioretec is reshaping orthopedic care through its commitment to transforming how implants function within the body. Focused on healing through absorption, Bioretec strives to introduce patient-friendly solutions that enhance surgical outcomes and foster sustainable orthopedic treatments.
For more insight into Bioretec’s innovative technologies and product offerings, individuals are encouraged to visit their official website.
Frequently Asked Questions
What is the TPT status granted to Bioretec?
The TPT status allows Bioretec’s RemeOs™ Trauma Screw to receive additional reimbursement from Medicare, supporting new orthopedic technologies.
What is highlighted in the updated HCPCS code C1741?
HCPCS code C1741 focuses on absorbable metallic bone fixation devices, reflecting Bioretec's innovation in this field.
How does the TPT payment benefit healthcare facilities?
This payment provides extra reimbursement, making it easier for hospitals to adopt innovative technologies without significant budget constraints.
What does Bioretec’s RemeOs™ Trauma Screw do?
It is designed to promote bone healing and gradually degrade, eliminating the need for metal removal surgeries while supporting effective recovery.
What future innovations can be expected from Bioretec?
Bioretec continues to develop advanced biodegradable technologies aimed at improving orthopedic care and patient outcomes effectively.
